New approaches to the endocrine prevention and treatment of breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78794
Title:
New approaches to the endocrine prevention and treatment of breast cancer.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Howell, Sacha J; Evans, D Gareth R
Abstract:
All major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.
Affiliation:
CRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
New approaches to the endocrine prevention and treatment of breast cancer. 2003, 52 Suppl 1:S39-44 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
Jul-2003
URI:
http://hdl.handle.net/10541/78794
DOI:
10.1007/s00280-003-0645-5
PubMed ID:
12819938
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorHowell, Sacha J-
dc.contributor.authorEvans, D Gareth R-
dc.date.accessioned2009-08-27T08:21:41Z-
dc.date.available2009-08-27T08:21:41Z-
dc.date.issued2003-07-
dc.identifier.citationNew approaches to the endocrine prevention and treatment of breast cancer. 2003, 52 Suppl 1:S39-44 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid12819938-
dc.identifier.doi10.1007/s00280-003-0645-5-
dc.identifier.urihttp://hdl.handle.net/10541/78794-
dc.description.abstractAll major endocrine prevention approaches act via the estrogen receptor (ER). A simple hypothesis concerning ER expression and breast cancer risk is outlined. We review breast cancer prevention trials with tamoxifen, raloxifene, aromatase inhibitors, and ovarian suppression. Current and planned endocrine prevention trials in populations of pre- and postmenopausal women at risk of breast cancer are summarized and endocrine therapy after primary surgery and for advanced disease discussed.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshRaloxifene-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshRisk-
dc.subject.meshSelective Estrogen Receptor Modulators-
dc.subject.meshTamoxifen-
dc.subject.meshTreatment Outcome-
dc.titleNew approaches to the endocrine prevention and treatment of breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, Christie Hospital NHS Trust, University of Manchester, Wilmslow Road, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.